Down 17% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and diagnostic stocks a median 5%.
GRAL's Quality Score rose 1 point on Tue, Nov 10, to 5. Trading was quieter than usual (2 chart checks started).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 29.5% more shares than a year ago |
| Latest filing | 10-Q, Nov 5 |
Tue Nov 10: UBS Global Healthcare Conference 2026Investor conference · date confirmed.
After its last 4 reports it closed -16.7% on average, higher 1 of 4 times.
Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
GRAL is #14 of 18 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 14 |
Free cash flow over four quarters: GRAL -$312M, LH $1.29B.
Expected to report Thu Feb 18, after the close (in 100 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $37.5M, 4% more than a year ago.
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Screening Revenue | $37.3M | $42.6M | $32.8M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
No outlook figures read from this release.
Sales grew 38% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 5.8% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -16.8% | -17.1% | not yet |
| Aug 5, 2026 | -8.3% | -14.5% | -7.1% |
| May 5, 2026 | +2.9% | +15.3% | +13.9% |
Sales grew every year from 2022 to 2025, to $147M. It lost money in each of the four years.
RSI 46.9, MACD below signal, above both averages. Not scored.
2 insiders sold $4.7M across 3 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: GRAL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
GRAL scores 5 today, which Breakaway calls Below Average. It is #14 of 18 in Services-Medical Laboratories by Quality Score, with 4 of 14 chart checks firing. Down 17% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and diagnostic stocks a median 5%. Shares: 29.5% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
GRAL scores 5 today, which Breakaway calls Below Average (0 to 5). That is #14 of 18 in Services-Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GRAL's 5.
2 insiders sold $4.7M across 3 filings in the last 6 months. No open-market buys on record. The newest is Aaron Freidin, Chief Financial Officer, who sold $3.5M on Oct 5. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.